Comparison of the action of NSC 680410 and STI571 in chronic myelogenous leukemia cells in vitro.

被引：0
|
作者：
Mow, BM
Hallgren, CG
Svingen, PA
Tefferi, A
Sausville, EA
Kaufmann, SH
机构：
[1] Mayo Clin, Div Hematol, Rochester, MN USA
[2] Mayo Clin, Div Oncol Res, Rochester, MN USA
[3] NCI, Dev Therapeut Program, Bethesda, MD 20892 USA
来源：
BLOOD | 2000年 / 96卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1493
引用
收藏
页码：346A / 346A
页数：1
相关论文
共 50 条
  • [41] Apoptotic synergism between histone deacetylase (HDAC) inhibitor and imatinib mesylate (STI571, Glivec®) on chronic myelogenous leukemia (CML) cell lines
    Kim, Byung-Su
    Choi, Yong-Hee
    Kim, Young Jue
    Bae, Eun Kyung
    Ahn, Kwang-Sung
    Park, Seonyang
    Kim, Byoung Kook
    Kim, Yeul Hong
    Yoon, Sung-Soo
    ANNALS OF ONCOLOGY, 2004, 15 : 159 - 159
  • [42] Regression of the Philadelphia chromosome (bcr/abl)-positive myelo- and megakaryopoiesis after Imatinib (STI571) therapy in chronic myelogenous leukemia (CML)
    Thiele, J
    Kvasnicka, HM
    Varus, E
    Kriener, S
    Engels, K
    Staib, P
    Ollig, ES
    Griesshammer, M
    Waller, CF
    Pfeifer, H
    Schmitt-Gräff, A
    PATHOLOGE, 2004, 25 (06): : 428 - 435
  • [43] The Effects of Genistein and STI571 (Imatinib) on Signal Protein Levels Affecting Chronic Myeloid Leukemia
    Armutcuoglu, Nur Erden
    Kasap, Yesim Korkmaz
    Yurtcu, Erkan
    GAZI MEDICAL JOURNAL, 2018, 29 (03): : 187 - 190
  • [44] Treatment of chronic myeloid leukemia (CML) with STI571 in patients age ≥60 years.
    Cortes, J
    Talpaz, M
    O'Brien, SM
    Manero, G
    Thomas, D
    Faderl, S
    Capdeville, R
    Kantarjian, HM
    BLOOD, 2001, 98 (11) : 256B - 256B
  • [45] Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells
    J Topaly
    WJ Zeller
    S Fruehauf
    Leukemia, 2001, 15 : 342 - 347
  • [46] Differential regulation of the p70 S6 kinase pathway by interferon αt (IFNα) and imatinib mesylate (STI571) in chronic myelogenous leukemia cells
    Parmar, S
    Smith, J
    Sassano, A
    Uddin, S
    Katsoulidis, E
    Majchrzak, B
    Kambhampati, S
    Eklund, EA
    Tallman, MS
    Fish, EN
    Platanias, LC
    BLOOD, 2005, 106 (07) : 2436 - 2443
  • [47] Sensitivity to the abl inhibitor STI571 in fresh leukaemic cells obtained from chronic myelogenous leukaemia patients in different stages of disease
    Gambacorti-Passerini, C
    Barni, R
    Marchesi, E
    Verga, M
    Rossi, F
    Rossi, F
    Pioltelli, P
    Pogliani, E
    Corneo, GM
    BRITISH JOURNAL OF HAEMATOLOGY, 2001, 112 (04) : 972 - 974
  • [48] Imatinib mesylate (STI571) considerably affects normal human bone marrow stromal cell growth in vitro.
    Melzer, D
    Neumann, U
    Ebell, W
    Seeger, K
    Neuhaus, P
    Gaedicke, G
    Brummendorf, TH
    Scheding, S
    BLOOD, 2004, 104 (11) : 641A - 641A
  • [49] Chronic myeloid leukemia in a patient with chronic idiopathic thrombocytopenic purpura: Rapid response to imatinib mesylate (STI571)
    Imashuku, S
    Morimoto, A
    Kuriyama, K
    Kano, G
    Hibi, S
    Todo, S
    MEDICAL AND PEDIATRIC ONCOLOGY, 2003, 41 (02): : 159 - +
  • [50] Isolated central nervous system relapse in a patient with chronic myeloid leukemia with lymphoid blast crisis under STI571 due to low penetration of STI571 into the cerebrospinal fluid.
    Petzer, AL
    Gunsilius, E
    Hayes, M
    Stockhammer, G
    Duba, HC
    Schneller, F
    Gruenewald, K
    Poewe, W
    Gastl, G
    BLOOD, 2001, 98 (11) : 141A - 141A
12345